Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies affecting mainly the middle aged and elderly. [1] [2] [3] The majority of affected patients die within 1-2 years due to overt leukemic transformation or the complication of hematocytopenias. The development of hematocytopenias despite the presence of cellular marrow is thought to be due to ineffective hematopoiesis probably associated with frequent apoptosis of hematopoietic cells in the bone marrow. 4, 5 In vitro examination revealed that the proliferation as well as death of hematopoietic cells is regulated by various proteins with stimulatory and inhibitory activities. marrow cells may disrupt hematopoiesis by exerting apoptosis on hematopoietic cells. Cytokines are a family of proteins that regulate cellular proliferation and differentiation by binding to specific receptors on target cells. In the bone marrow of patients with MDS, clonal disorders with trilineage dysplasia, interactions of abnormal clone cells with stromal cells including macrophages, fibroblastic cells and endothelial cells may be important for cytokine production. 6 Hematopoietic cells as well as stromal cells have been reported to express a wide range of substances which may play complex regulatory roles in hematopoiesis. [7] [8] [9] We have reported previously that the number of macrophage lineage cells significantly increased in the bone marrow of MDS patients as compared with that of the control or de novo AML bone marrow. 10 Furthermore, bone marrow macrophages express tumor necrosis factor (TNF)␣ and interferon (IFN)-␥ which have an accelerating effect on apoptosis. 11 Regarding the induction of apoptosis, two factors are known to bind to receptors, induce apoptosis and kill the cells within hours. 12, 13 One of them is TNF-␣ and the other is Fas ligand (FasL). Fas, the receptor for FasL, is a type I membrane protein and a member of the TNF receptor family. Binding of FasL to Fas or cross-linking of Fas with agonistic antibodies induces apoptosis in Fas-bearing cells. Thus, in the present study, the contribution of the Fas-FasL system to the induction of apoptosis was examined in bone marrow samples from MDS patients. To further clarify the cells responsible for apoptosis, the distribution and cell type of Fas or FasL expressing cells was determined in the bone marrow of MDS.
Recently, reverse transcriptase (RT)-polymerase chain reaction (PCR) amplification has proven to be a sensitive method for the detection of very low expression of mRNA from limited clinical samples. 14, 15 This study therefore attempted to investigate Fas and FasL in MDS in vivo using RT-PCR and then to immunohistochemically demonstrate the localization of Fas and/or FasL producing cells in the bone marrow.
Materials and methods

Patients
Bone marrow samples of trephin biopsy and partly autopsy material were taken from 17 patients with MDS; four with refractory anemia (RA), one with RA with ring sideroblasts (RARS), four with RA with excess of blasts (RAEB), five with RAEB in transformation (RAEB-T) and three with chronic myelomonocytic leukemia (CMMoL). The samples were embedded in OCT compound (purchased from Sakura, Tokyo, Japan), frozen using liquid nitrogen, cryosectioned and investigated for frequency of apoptotic cells and the expression of Fas and FasL. A diagnosis of MDS was based on FAB criteria. 1 None of the patients had received specific therapeutic agents prior to the study. 
Detection of apoptotic cells by end labeling method
To determine apoptotic cells on frozen tissue sections by terminal deoxytransferase (TdT)-mediated dUTP nick end labeling (TUNEL), the in situ cell death detection kit, fluorescein (Boehringer Mannheim, Mannheim, Germany) was used. The method was a modified version of the biotin-peroxidase system detection method described previously. 16 Briefly, frozen sections were fixed with 4% paraformaldehyde solution for 20 min, washed with phosphate-buffered saline (PBS), incubated in 0.1% sodium citrate-0.1% Triton X-100 for 2 min, washed with PBS and then incubated with fluorescein isothiocyanate (FITC)-labeled dUTP and TdT at 37°C for 60 min. Sections were then observed by fluorescein microscopy and the TUNEL-positive cell ratio was determined by dividing the number of positively stained cells by the total cell number (counting more than 500 cells).
Preparation of RNA samples and amplification method RNA was isolated from frozen bone marrow samples by a guanidium isothiocyanate solubilization/LiCl precipitation procedure. Tissue RNA (250 ng) was used as a template for the amplification reactions. Oligonucleotides as specific primers for Fas and FasL were synthesized by a commerical laboratory (Life Technologies Oriental, Tokyo, Japan). The sequences of primers were as follows: Fas: 5′ PCR primer CCTACCTCTGGTTCTTACGT, 3′ PCR primer GGCTTTGTC-TGTACTCCT; FasL: 5′ PCR primer CAAGTCCAACTCAAG-GTCCATGCC, 3′ PCR primer CAGAGAGAGCTCAGATACG-TTTGAC; ␤-actin: 5′ PCR primer AAGAGAGGCA-TCCTCACCCT, 3′ PCR primer TACATGGCTGGGGTG-TTGAA. The expected sizes of PCR products were 265 bp for Fas, 345 bp for FasL and 218 bp for ␤-actin. Complementary (c)DNA was synthesized by using Rous-associated virus reverse transcriptase (Takara Biomedicals, Kyoto, Japan). The PCR reaction was performed as described. 9, 14, 15 As a control reaction of PCR, ␤-actin was also used in each run. Briefly, 250 ng of the RNA was used for RT-PCR. For cDNA synthesis, 250 ng in 20 l of sample RNA solution was heated at 65°C for 5 min and cooled rapidly. After adding 20 U of ribonuclease inhibitor (Takara, Japan), 5 l of 2 mM dNTP (dATP, dCTP, dGTP, dTTP; Perkin Elmer, Applied Biosystems Divisions, Foster City, CA, USA) and 3 U of Rous-associated virus reverse transcriptase (Takara, Japan), the mixture was incubated at 42°C for 60 min, then heated at 95°C for 5 min and cooled rapidly. The PCR reaction mixture contained 5 l of cDNA, 2.5 l of 10 × PCR buffer, 11 l of 20 mM MgCl 2 , 2 l of 2 mM dNTP, 11.35 l of DEPC-water, 100 pM 5′ and 3′ primer, and 2.5 U of thermostable Taq polymerase (Perkin Elmer Cetus, Norwalk, CT, USA). The amplification was achieved with a DNA thermal cycler (Perkin Elmer Cetus). After denaturing at 94°C for 10 min, the amplification was conducted for 35 cycles at 94°C for 30 s, 55°C for 30 s and 72°C for 60 s. This was followed by re-extension for 10 min at 72°C. Ten milliliter aliquots of the product samples were analyzed by electrophoresis on a 1.8% agarose gel and visualized by UV fluorescence after staining with ethidium bromide. X174/HaeIII-cut DNA was run in parallel as a molecular weight marker. Then, the density of bands was measured by scanning imager, Image Quant (Molecular Dynamics, Sunnyvale, CA, USA).
Immunohistochemistry
To examine the distribution of Fas or FasL expressing cells in the bone marrow, a polyclonal rabbit antibody against Fas (BIOMOL Research Laboratories, Plymouth Meeting, PA, USA) or a monoclonal antibody against FasL (C-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was applied to frozen sections. Sections were then incubated with fluorescein isothiocyanate (FITC)-conjugated anti-rabbit IgG antibody (DAKO, Glostrup, Denmark) or FITC-conjugated anti-mouse IgG antibody (Pharmingen, San Diego, CA, USA). For double staining of Fas or FasL immunostaining and the TUNEL method, immunostaining was performed first using tetramethyl rhodamine isothiocyanate (TRITC)-conjugated secondary antibodies (DAKO) and then, TUNEL staining was performed using FITC-labeled dUTP. To define the cell type on the same sections, the distribution of hematopoietic precursor cells, myeloid series of cells, erythroid series of cells, or bone marrow macrophages was determined by double immunostaining of Fas/FasL with anti-CD34 antibody (NU4A-1; Nichirei, Tokyo, Japan), anti-neutrophil elastase antibody (DAKO), antiglycophorin A antibody (DAKO), or anti-CD68 antibody (KP-1; DAKO). This was followed by incubation with TRITC-conjugated anti-mouse IgG (DAKO). Control procedures included the substitution of equivalent concentrations of a heavy chainmatched monoclonal antibody of irrelevant specificity and the staining of bone marrow sections from control cases. Sections were observed and analyzed using a confocal laser scanning microscope (TCS NT; Leica, Heerbrugg, Switzerland).
Results
Frequency of apoptotic cells in the bone marrow
To confirm the frequent apoptosis in bone marrow cells of MDS patients, the TUNEL-positive cell ratio was determined and compared in frozen tissue sections between MDS and control bone marrow (Figure 1a and b) . As shown in Table 1 , in bone marrow of MDS cases, more than 12% of cells were TUNEL positive (12.6-25.3%, mean ± s.d.; 17.2 ± 4.9%), whereas less than 6% were positive in control bone marrow (1.1-5.6%, mean ± s.d.; 3.4 ± 1.5%). The difference between MDS and control cases was significant by Student's t-test (P Ͻ 0.001). Among subtypes of MDS cases, the TUNEL-positive cell ratio of RA or RAEB cases was larger than that of RAEB-T or CMMoL cases. The differences were significant between RAEB and RAEB-T (P Ͻ 0.01) and RAEB and CMMoL (P Ͻ 0.02).
Expression of mRNA for Fas or FasL in the bone marrow
So as to examine very low levels of mRNA expression in bone marrow cells, RT-PCR was performed using RNA from frozen bone marrow tissues. This method revealed the expression of Fas or FasL mRNA, as defined by a 265 bp and a 345 bp PCR Differences were significant by Student's t-test *P Ͻ 0.001, **P Ͻ 0.01, ***P Ͻ 0.02.
product, respectively. As shown in Figure 2 , control cases showed no expression of Fas mRNA (lanes 1-3) , while the majority of MDS cases exhibited positive signals for Fas mRNA (lanes 4-7). In MDS cases developing overt leukemia, signals for Fas expression were very weak (lanes 8 and 9). As shown in Figure 2 , bone marrow samples from MDS patients showed strong expression of FasL mRNA, whereas those from control cases showed no distinct expression, although one case exhibited a very weak band for FasL mRNA. As expected, signals for ␤-actin (positive control) were detected in all the bone marrow samples by RT-PCR reaction. However, because the bands for ␤-actin in lanes 1-3 and 9 were weak compared to the bands in other lanes, we measured the density of bands for Fas as well as ␤-actin of each lane and calculated the ratio of the density Fas/␤-actin. In control cases, the ratio was 0.13 ± 0.03 (mean ± s.d.), while the ratio was 0.84 ± 0.17 in MDS cases. Difference was significant by Student's t-test (P Ͻ 0.002). As expected, the ratio of MDS cases developing overt leukemia (0.23 ± 0.11) was significantly lower than those of MDS cases (P Ͻ 0.05). Similarly, the ratio of the density of bands FasL/␤-actin was calculated as 0.19 ± 0.10 in control, 1.10 ± 0.43 in MDS cases and 0.98 ± 0.08 in MDS cases developing overt leukemia. Differences were significant between control and MDS (P Ͻ 0.03) and control and MDS cases developing overt leukemia (P Ͻ 0.005).
The case distribution of up-regulation of Fas as well as FasL mRNA in bone marrow samples is summarized in Table 2 . All 
Discussion
Bone marrow cells from MDS patients are known to have unbalanced growth characteristics [17] [18] [19] [20] but the underlying mechanisms causing them are still unclear. A high rate of apoptosis explains the ineffective hematopoiesis observed in MDS. Using plastic-embedded bone marrow biopsy samples and an in situ end labeling technique, Raza et al 4, 21 found that у 75% of all hematopoietic cells were apoptotic in the bone marrow of MDS patients. Kanter et al 22 also reported massive apoptosis in MDS bone marrow cells of formalinfixed paraffin-embedded tissue sections. However, much fewer cells were evaluated as apoptotic based on morphology 23 or a TUNEL technique on bone marrow smears. 24, 25 In the present study, we examined the apoptotic cells by the TUNEL method using frozen bone marrow samples and demonstrated that the mean percentage of apoptotic cells in the bone marrow of MDS was 17.2% which was comparable to the rate determined by TUNEL method using bone marrow smears. Although there are no clear explanations for the difference in the rate of apoptosis observed in various studies, the main difference may be ascribed to the fixation of bone marrow samples. 24 Alternatively, the apoptotic cells may immediately be phagocytized by macrophages and such figures may not be detected in frozen sections.
In the present study, results of Fas/FasL expression analysis by RT-PCR technique correlated well with those by immunohistochemical staining. However, in one case of MDS, RT-PCR method failed to demonstrate FasL expression by bone marrow cells, while bone marrow cells of the case were positively stained with immunohistochemical staining. This may result from the fact that the number of FasL expressing cells in this case was rather small because the distinct expression was limited to CD68-positive macrophage lineage cells.
The death of cells during embryogenesis, metamorphosis, endocrine-dependent tissue atrophy and normal tissue turnover is programmed, mediated by a process of apoptosis. 13 However, apoptosis is also mediated by a cytokine and its receptor in some cases. 4 Binding of FasL to Fas or cross-linking of Fas with agonistic antibodies induces apoptosis in Fas-bearing cells. 12, 26, 27 On the other hand, TNF-␣ induces apoptosis and activates transcription factor NF-B.
12,27 Furthermore, TGF-␤ induced apoptosis in a myeloid leukemic cell line. [28] [29] [30] Previously, we have reported overexpression of TNF-␣ and IFN-␥ in the bone marrow of MDS patients. 11 Raza et al 4, 21 also observed an increase of TNF-␣, TGF-␤ and IL-1␤ in the bone marrow of MDS. Sato et al 31 have reported that IFN-␥,TNF-␣ and FasL can mediate potent inhibitory signals in hematopoietic cells. Fas antigen expression on CD34-positive bone marrow cells was increased by TNF-␣ and IFN-␥ in vitro. Such a mechanism would be consistent with the observation by Maciejewski et al 32, 33 that Fas receptor on CD34-positive hematopoietic precursor cells is upregulated by various cytokines including TNF-␣, and with the suggestion that subsequent cell death is Fas-mediated.
Lepelley et al 24 have found increased Fas antigen expression in marrow cells (mostly erythroblasts) in about 50% of MDS patients. Gersuk et al 34 have shown that marrow mononuclear cells of patients with MDS strongly expressed Fas and FasL compared to the cells of a normal individual. By flow cytometric analysis, the fluorescence intensity for Fas on bone marrow cells from MDS patients was stronger than in normal controls, suggesting a higher antigen density on the cell surface. 34 The number of FasL expressing bone marrow mononuclear cells of MDS patients was also increased com- pared to control bone marrow cells. 34 Recently, Bouscary et al 25 have shown that patients with MDS had upregulation of Fas expression on total bone marrow nuclear cells, CD34-positive, CD33-positive and glycophorin-positive bone marrow cells compared to controls. No statistical correlation could be found between Fas expression and apoptosis rate. Fas expression did not correlate to the FAB subtype but the expression intensity on CD34-positive cells inversely correlated with the number of blasts. Thus, they have suggested that leukemic blast cells lose Fas antigen expression with progression of myelodysplasia. The present data on Fas expression by MDS bone marrow cells were basically consistent with their data.
It is possible that the release of regulatory cytokines such as TNF-␣, IFN-␥, TGF-␤, or others by bone marrow stromal cells, 11 results in the upregulation of not only Fas, but also FasL in hematopoietic cells. Alternatively, MDS bone marrow cells in the process of their evolution, may spontaneously upregulate Fas, FasL or both, or show increased responsiveness to exogenous cytokines thereby facilitating upregulation. 34 Bogdanovic et al 23 observed that apoptosis developed in 'clusters' of marrow cells and speculated that this phenomenon is related to the production of cytokines such as TNF-␣ or TGF-␤. These findings were consistent with the present data suggesting that Fas-positive cells were mainly hematopoietic cells and FasL-positive cells were a mixture of hematopoietic cells as well as bone marrow macrophages. These results indicate that the Fas-FasL system can work in both an autocrine (hematopoietic cell-hematopoietic cell interaction) and paracrine manner (hematopoietic cell-stromal cell interaction) in the bone marrow of MDS patients, although further study for the function and network of other factors may be necessary to clarify the precise mechanism of apoptosis in the bone marrow of MDS.
